ABBOTT LABORATORIES (ABT)

Abbott Laboratories is an Illinois corporation, incorporated in 1900. Its principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott agreed to acquire Exact Sciences Corporation, a deal expected to let it enter the cancer diagnostics market. The acquisition remains subject to customary closing conditions, including Exact Sciences shareholder approval and regulatory clearances.

Abbott reports four segments. Established Pharmaceutical Products covers branded generic pharmaceuticals sold outside the U.S. in emerging markets, in gastroenterology (Creon, Duspatal), women's health (Duphaston, Femoston), cardiovascular and metabolic (Synthroid, TriCor, Lipanthyl), pain and central nervous system, and respiratory areas (including the Influvac vaccine), plus biosimilars. Diagnostic Products includes core laboratory systems (Alinity, ARCHITECT), molecular diagnostics (Alinity m), point-of-care systems (i-STAT), rapid diagnostics (BinaxNOW, ID NOW, Panbio), cardiometabolic and toxicology testing, and informatics and automation solutions. Nutritional Products includes infant formula (Similac, EleCare), adult and pediatric nutritionals (Ensure, Glucerna, PediaSure, Pedialyte), and enteral feeding products for healthcare institutions (Jevity, Osmolite). Medical Devices includes rhythm management (pacemakers, ICDs, the Aveir leadless pacemaker), electrophysiology, heart failure (HeartMate, CardioMEMS), vascular (XIENCE stents), structural heart (MitraClip, TriClip, Navitor), diabetes care and continuous glucose monitoring (FreeStyle Libre, Lingo), and neuromodulation devices for chronic pain and movement disorders.

Customers vary by segment. Pharmaceutical products are sold to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and retailers. Diagnostics go to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, and government agencies. Nutritional products reach consumers, institutions, wholesalers, retailers, and healthcare facilities. Medical devices are sold to wholesalers, hospitals, ambulatory surgery centers, physicians' offices, consumers, and distributors, directly or through distributors outside the U.S. Abbott operates in more than 160 countries and has no single customer whose loss would materially harm it. Its business has no significant seasonality.

Abbott buys raw materials and supplies from numerous suppliers in the U.S. and worldwide and has had no recent significant shortages. It distributes through Abbott-owned distribution centers, public warehouses, and third-party distributors. It holds many patents and trademarks, with patents expiring between 2026 and 2046, though no single one is material to the business as a whole. Competitors include other pharmaceutical, healthcare, and diversified consumer companies, generic drug makers, and private label and local manufacturers, competing on innovation, price, performance, and service. The business is heavily regulated by the FDA and comparable agencies abroad, and by healthcare reimbursement and pricing rules. Abbott employed about 115,000 people at December 31, 2025, 69% of them outside the U.S. The text does not state its headquarters location.